Zanubrutinib approved for marginal zone lymphoma


BeiGene announced that its drug Brukinsa, or zanubrutinib, received the FDA's accelerated approval as a treatment for relapsed or refractory marginal zone lymphoma in adults who have undergone at least one anti-CD20-based regimen. Zanubrutinib is also being tested as a treatment for chronic lymphocytic leukemia.

Full story:

AIChE SmartBrief

Chemical engineering news

Designed specifically for chemical engineers, AIChE SmartBrief is a FREE weekly e-mail newsletter. It helps chemical engineers stay informed on the business and technology developments affecting our profession.